{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:30:42Z","timestamp":1783582242275,"version":"3.55.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"17","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The key role of inflammation in the pathogenesis of coronary artery disease (CAD) is an urgent call for innovative treatments. Several trials have proposed colchicine as a therapeutic option for secondary prevention in CAD patients but its utilization is hampered by fears about drug-related adverse events (DAEs) and conflicting evidences. The aim of this meta-analysis was to consolidate evidence on the efficacy and safety of colchicine for secondary prevention in patients with CAD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>A systematic search in electronic bibliographic databases of Medline, Scopus, Embase, and the Cochrane Library was performed to identify randomized controlled trials (RCTs) assessing the cardiovascular effects of colchicine in CAD patients, compared with placebo. Outcomes of interest were the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) and DAEs. Estimates were pooled using inverse-variance random-effects model. A total of 11 RCTs, including 12\u00a0869 patients, were identified as eligible. A total of 6501 patients received colchicine, while 6368 received placebo. After a median follow-up of 6\u2009months (interquartile range, 1\u201316), patients receiving colchicine had a lower risk of MACCE [6% vs. 8.8%, relative risk (RR) = 0.67, 95% confidence interval (CI) 0.56\u20130.80, I2\u2009=\u200919%], myocardial infarction (3.3% vs. 4.3%, RR\u2009=\u20090.76, 95% CI 0.61\u20130.96, I2\u2009=\u200917%), coronary revascularization (2.9% vs. 4.2%, RR\u2009=\u20090.61, 95% CI 0.42\u20130.89, I2\u2009=\u200940%), stroke (0.4% vs. 0.9%, RR\u2009=\u20090.48, 95% CI 0.30\u20130.77, I2\u2009=\u20090%), hospitalization for cardiovascular cause (0.9% vs. 2.9%, RR\u2009=\u20090.32, 95% CI 0.12\u20130.87, I2\u2009=\u20090%). Colchicine was associated with an increased risk of gastrointestinal DAEs (11% vs. 9.2%, RR\u2009=\u20091.67, 95% CI 1.20\u20132.34, I2\u2009=\u200976%), myalgia (18% vs. 16%, RR = 1.16, 95% CI 1.02\u20131.32, I2\u2009=\u20090%) and DAEs-related discontinuation (4.1% vs. 3%, RR = 1.54, 95% CI 1.02\u20132.32, I2\u2009=\u200965%). However, gastrointestinal DAEs and discontinuation may be prevented with a lower daily dose. Colchicine did not increase the risk of cardiovascular death (0.7% vs. 1%, RR\u2009=\u20090.73, 95% CI 0.45\u20131.21, I2\u2009=\u200914%), all-cause death (2% vs. 1.9%, RR\u2009=\u20091.01, 95% CI 0.71\u20131.43, I2\u2009=\u200916%), or other DAEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The use of colchicine in patients with CAD is safe and efficacious for MACCE prevention.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwab045","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T20:09:30Z","timestamp":1615061370000},"page":"1916-1925","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy and safety of colchicine for the prevention of major cardiovascular and cerebrovascular events in patients with coronary artery disease: a systematic review and meta-analysis on 12\u00a0869 patients"],"prefix":"10.1093","volume":"28","author":[{"given":"Alessandro","family":"Andreis","sequence":"first","affiliation":[{"name":"Department of Cardiovascular and Thoracic, University Cardiology, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Corso Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-0245","authenticated-orcid":false,"given":"Massimo","family":"Imazio","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic, University Cardiology, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Corso Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Piroli","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic, University Cardiology, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Corso Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Avondo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic, University Cardiology, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Corso Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Casula","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic, University Cardiology, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Corso Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Paneva","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic, University Cardiology, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Corso Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano Maria","family":"De Ferrari","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic, University Cardiology, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Corso Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"2022020822412933700_zwab045-B1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2022020822412933700_zwab045-B2","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa624","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"key":"2022020822412933700_zwab045-B3","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"2022020822412933700_zwab045-B4","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"2022020822412933700_zwab045-B5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosis.2019.01.026","article-title":"The impact of sedentary behavior patterns on carotid atherosclerotic burden: implications from the Corinthia epidemiological study","volume":"282","author":"Lazaros","year":"2019","journal-title":"Atherosclerosis"},{"key":"2022020822412933700_zwab045-B6","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/heartjnl-2020-317108","article-title":"Colchicine for acute and chronic coronary syndromes","volume":"106","author":"Imazio","year":"2020","journal-title":"Heart"},{"key":"2022020822412933700_zwab045-B7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/jcm8081109","article-title":"Inflammation as a therapeutic target in atherosclerosis","volume":"8","author":"Nguyen","year":"2019","journal-title":"J Clin Med"},{"key":"2022020822412933700_zwab045-B8","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2022020822412933700_zwab045-B9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMe1709904","article-title":"Targeting inflammation in coronary artery disease","volume":"377","author":"Harrington","year":"2017","journal-title":"N Engl J Med"},{"key":"2022020822412933700_zwab045-B10","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1093\/eurheartj\/ehz961","article-title":"Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease","volume":"41","author":"Liberale","year":"2020","journal-title":"Eur Heart J"},{"key":"2022020822412933700_zwab045-B11","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"2022020822412933700_zwab045-B12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/0003319719855165","article-title":"Methotrexate for cardiovascular risk reduction: the right choice?","volume":"71","author":"Reiner","year":"2020","journal-title":"Angiology"},{"key":"2022020822412933700_zwab045-B13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2022020822412933700_zwab045-B14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.2174\/1381612824666180116101823","article-title":"The role of colchicine in pericardial syndromes","volume":"24","author":"Lazaros","year":"2018","journal-title":"Curr Pharm Des"},{"key":"2022020822412933700_zwab045-B15","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/archinte.165.17.1987","article-title":"Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial","volume":"165","author":"Imazio","year":"2005","journal-title":"Arch Intern Med"},{"key":"2022020822412933700_zwab045-B16","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.105.542738","article-title":"Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial","volume":"112","author":"Imazio","year":"2005","journal-title":"Circulation"},{"key":"2022020822412933700_zwab045-B17","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1093\/eurheartj\/ehq319","article-title":"COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial","volume":"31","author":"Imazio","year":"2010","journal-title":"Eur Heart J"},{"key":"2022020822412933700_zwab045-B18","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.2014.11026","article-title":"Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial","volume":"312","author":"Imazio","year":"2014","journal-title":"JAMA"},{"key":"2022020822412933700_zwab045-B19","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/circ.83.4.2064652","article-title":"Treatment of acute or recurrent pericarditis with colchicine","volume":"83","author":"Millaire","year":"1991","journal-title":"Circulation"},{"key":"2022020822412933700_zwab045-B20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/14779072.2019.1691916","article-title":"Contemporary diagnosis and treatment of recurrent pericarditis","volume":"17","author":"Andreis","year":"2019","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2022020822412933700_zwab045-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2459\/JCM.0000000000001079","article-title":"Colchicine for the treatment of cardiovascular diseases: old drug, new targets","volume":"22","author":"Andreis","year":"2021","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2022020822412933700_zwab045-B22","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/0735-1097(92)90624-V","article-title":"Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty","volume":"19","author":"O'Keefe","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2022020822412933700_zwab045-B23","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacc.2013.01.055","article-title":"Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients","volume":"61","author":"Deftereos","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022020822412933700_zwab045-B24","doi-asserted-by":"crossref","first-page":"e008717","DOI":"10.1161\/CIRCINTERVENTIONS.119.008717","article-title":"Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial","volume":"13","author":"Shah","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"2022020822412933700_zwab045-B25","article-title":"Colchicine therapy in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials","author":"Al-Abdouh","year":"2020","journal-title":"Coron Artery Dis"},{"key":"2022020822412933700_zwab045-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.carrev.2020.06.004","article-title":"Safety and efficacy of colchicine in patients with coronary artery disease: a systematic review and meta-analysis","volume":"23","author":"Ullah","year":"2021","journal-title":"Cardiovasc Revasc Med"},{"key":"2022020822412933700_zwab045-B27","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2022020822412933700_zwab045-B28","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"2022020822412933700_zwab045-B29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2022020822412933700_zwab045-B30","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS Randomized Clinical Trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"2022020822412933700_zwab045-B31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11239-011-0637-y","article-title":"Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial","volume":"33","author":"Raju","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"2022020822412933700_zwab045-B32","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circulation"},{"key":"2022020822412933700_zwab045-B33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.acvd.2016.10.004","article-title":"COLIN trial: value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response","volume":"110","author":"Akodad","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"2022020822412933700_zwab045-B34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2019.06.003","article-title":"The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction","volume":"215","author":"Hennessy","year":"2019","journal-title":"Am Heart J"},{"key":"2022020822412933700_zwab045-B35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022020822412933700_zwab045-B36","doi-asserted-by":"crossref","first-page":"e002128","DOI":"10.1161\/JAHA.115.002128","article-title":"Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome","volume":"4","author":"Mart\u00ednez","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2022020822412933700_zwab045-B37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2014update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2022020822412933700_zwab045-B38","doi-asserted-by":"crossref","DOI":"10.2459\/JCM.0000000000001157","article-title":"Adverse events of colchicine for cardiovascular diseases: a comprehensive meta-analysis of 14\u200a188 patients from 21 randomized controlled trials","author":"Andreis","year":"2021","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2022020822412933700_zwab045-B39","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1056\/NEJM198706183162502","article-title":"Colchicine myopathy and neuropathy","volume":"316","author":"Kuncl","year":"1987","journal-title":"N Engl J Med"},{"key":"2022020822412933700_zwab045-B40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5414\/CN108343","article-title":"Colchicine toxicity in renal patients\u2014are we paying attention?","volume":"86","author":"Medani","year":"2016","journal-title":"Clin Nephrol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/28\/17\/1916\/42379988\/zwab045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/28\/17\/1916\/42379988\/zwab045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T22:43:10Z","timestamp":1644360190000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/28\/17\/1916\/6199613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":40,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,3,29]]},"published-print":{"date-parts":[[2022,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwab045","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,3,29]]}}}